CTLA4 and metastatic melanoma: Clinical presentation of celiac disease: Falade et al. reported a case of a patient treated with combined CTLA-4 and PD-1 inhibition for metastatic melanoma who developed a fulminant manifestation of celiac disease with severe protein-losing enteropathy, resulting in hypotension and anasarca.